For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Somalogic, Incorporated

USPTO Granted Patents = 75

% Expired Patents = 17.3

CIPO Patents = 1

EPO Patents = 37

Trademarks = 5

Forward Citations = 1,037

Loading Chart...

Loading Chart...

84 inventors (with patents filed for the assignee):

Larry M Gold (35 out of 191 patents)

Dominic Zichi (25 out of 26 patents)

Nebojsa Janjic (24 out of 70 patents)

4. Daniel J Schneider (22 out of 33 patents)

5. Sheri K Wilcox (14 out of 15 patents)

6. Bruce Eaton (13 out of 36 patents)

7. Chris Bock (12 out of 12 patents)

8. Urs Ochsner (10 out of 12 patents)

9. John C Rohloff (9 out of 28 patents)

10. Thale Jarvis (8 out of 22 patents)

11. Amy D Gelinas (8 out of 8 patents)

12. Daniel W Drolet (8 out of 12 patents)

13. Malti P Nikrad (8 out of 8 patents)

14. Sheela M Waugh (7 out of 7 patents)

15. Chi Zhang (7 out of 8 patents)

Core Competencies:

Biomarkers

Aptamers

Multiplexed Analyses

Cancer Diagnosis

Lung Cancer

Chronic Obstructive Pulmonary Disease

Nucleic Acid Ligands

Quantum Sensors

Nonalcoholic Fatty Liver Disease

Tuberculosis

Fluorescence Detection

Microorganisms

75 patents: Sort by Forward Citations

1. 11249080 - Proteomic assay using quantum sensors (2022-02-15),

2. 11221340 - Lung cancer biomarkers and uses thereof (2022-01-11),

3. 11208663 - Post-selex modification methods (2021-12-28),

4. 11111495 - Method for generating aptamers with improved off-rates (2021-09-07),

5. 11041866 - Pancreatic cancer biomarkers and uses thereof (2021-06-22),

6. 10927380 - Oligonucleotides comprising modified nucleosides (2021-02-23),

7. 10808251 - Nucleic acid compounds for binding growth differentiation factor 11 (2020-10-20),

8. 10670611 - Cardiovascular risk event prediction and uses thereof (2020-06-02),

9. 10648972 - Multiplexed analyses of test samples (2020-05-12),

10. 10634679 - Compounds and methods for the synthesis of 5-(N-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidite for incorporation into a nucleic acid (2020-04-28),

11. 10620210 - Aptamers and diagnostic methods for detecting the EGF receptor (2020-04-14),

12. 10544419 - PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders (2020-01-28),

13. 10538771 - Compositions and methods for detecting microorganisms (2020-01-21),

14. 10526663 - Method of detecting a microorganism in a sample by a fluorescence based detection method (2020-01-07),

15. 10481155 - Proteomic assay using quantum sensors (2019-11-19),

Company Overview

Somalogic, Incorporated, based in Boulder, Colorado, specializes in advanced biomarker detection technologies. The company focuses on the development of innovative solutions utilizing aptamers and multiplexed analyses to enhance cancer diagnosis and monitor chronic diseases such as Chronic Obstructive Pulmonary Disease. By leveraging nucleic acid ligands and quantum sensors, Somalogic aims to transform the landscape of personalized medicine, providing critical insights into patient health and disease progression.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

75 Patents

#26 in Boulder, CO

#104 in Colorado

#4,911 in US

#10,020 in the World

Boulder, CO, United States of America

Somalogic, Incorporated

Forward Citations = 1,037

84 inventors:

Larry M Gold (35 out of 191 patents)

Dominic Zichi (25 out of 26 patents)

Nebojsa Janjic (24 out of 70 patents)

4. Daniel J Schneider (22 out of 33 patents)

5. Sheri K Wilcox (14 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Somalogic, Incorporated. Retrieved from https://idiyas.com/company/somalogic

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…